Evolus Inc at Bank of America Merrill Lynch Health Care Conference Transcript
(technical difficulty)
everybody. My name is Jason Gerberry, the U.S. pharma analyst here at Bank of America. I am pleased to be introducing our next company presenter. I'm joined by David Moatazedi, CEO of Evolus. David's got a few slides. So Evolus, for many of you who don't know, we'll call them a commercial stage company tomorrow, but right now, they're a late-stage player in the aesthetic dermatology space. And so David has a slide he wants to show and then we'll jump into Q&A.
Great. Thank you, Jason. And what's funny is I was about 2 weeks into my role here as President and CEO when I attended this BAML conference last year and had an opportunity to sit here across from you. So the company looks very different today than it did a year ago, roughly when I joined.
May I just take a few minutes for those of you that aren't familiar with Evolus to tell you a little bit about me and tell
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |